Kornimate/medical-research-clean huggingface dataset:
aortic valve regurgitation acquired after left ventricular assist device implantation: an outstanding in vivo model of valvular heart diseases

Conditions: Aortic Valve Regurgitation Acquired

Summary: to investigate histological structure and molecular changes involved on the onset of avd after left ventricular assist device (lvad) implantation and to compare them with those of patients operated on for severe aortic regurgitation. methods: bridge-to-transplant patients with avd post-lvad implantation are included. patients operated on for severe aortic regurgitation are included as control. clinical and tte data are compiled. samples of aortic valve are collected at the time of the intervention. rna-sequencing analysis is performed in lvad patients and variations of gene expression are validated by real time qpcr in both. blood sampling are performed pre-operatively and at one-month follow up to assess the plasma level of previously identified gene modulators. in-vitro studies exposing vics and vecs to several mechanical stimuli are performed for validation. conclusion(s) taking together, the in-vivo and in-vitro models would provide important information for the understanding of valve remodeling and disease. ecm gene modulators could represent pertinent molecular targets to stop the progression of avd


Eligibility criteria:
inclusion criteria: * patients with long-term left-ventricular assistance awaiting transplant * patients with severe aortic surgical spring deficiency * major patient exclusion criteria: * minor patient * pregnant or nursing women * major under guardianship * people in emergencies * persons not covered by the social security scheme
tranilast as a radiosensitizer in reradiation of nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; Recurrent Cancer

Summary: nasopharyngeal carcinoma is one of the high incidence head and neck cancer in southeast asia. radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can reach 80\~90%. however, for radiotherapy resistant patients with metastasis and recurrence, the survival prognosis decreased significantly, and the 5-year overall survival rate was only 20% - 40%. tranilast is an anti-allergic drug, which is clinically used to treat bronchial asthma and can inhibit fibroblasts α- sma and type i collagen expression. through experiments in vivo and in vitro, the investigators' research group has proved that tranilast can inhibit the activity of tumor related fibroblasts, reduce the radiotherapy resistance of nasopharyngeal carcinoma, and has the radiosensitizing effect of nasopharyngeal carcinoma. this result has been published in j exp clin cancer res (if=11.16). the investigators plan to carry out the clinical transformation of basic research, carry out a prospective intervention phase ii clinical trial, compare the objective remission rate of patients with recurrent nasopharyngeal carcinoma treated with previous radiotherapy, and explore the safety and effectiveness of using tranilast as a radiotherapy sensitizer for radiotherapy to resist the treatment of nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: 1. sign informed consent 2. at least 18 years old on the date of signing the informed consent 3. previously received standard radical radiotherapy and chemotherapy 4. recurrent nasopharyngeal carcinoma in situ or cervical lymph nodes confirmed by pathological biopsy and imaging examination 5. after multidisciplinary consultation, there was a clear indication for surgery, and the patient was informed and refused to accept surgical treatment 6）ecog ps：0/1 7) laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment. exclusion criteria: 1. after evaluation, it does not meet the indications of re-radiotherapy 2. unable to take oral medication 3. pregnancy or lactation 4. known allergy to tranilast 5. patients who are judged by the researcher as unsuitable to participate in this trial
quality of life in rectal cancer - a prospective multicenter cohort study

Conditions: Rectal Cancer; Quality of Life; Surgery

Summary: rectal cancer is a common type of cancer occuring more frequently in men but also common in women. almost 60% of the patients survive 5-years and the treatment has been continuously developed in the last three decades. the aim of the qolirect study is to increase the knowledge about symptoms, functional impairments, quality of life (qol) and psychological and socioeconomic burden in an unselected population of rectal cancer patients.

rectal cancer is more frequent in men than in women and is relatively uncommon before the age of 50. the prognosis for rectal cancer has improved over the last decades2. almost 60% of all patients survive more than five years, and because of advances in early detection and treatment, this number is expected to increase in the future1. treatment of rectal cancer varies depending on the stage of the disease at diagnosis. for some patients, operation is the only treatment. for others, surgery is combined with radiotherapy, chemotherapy or both. the two most common operative procedures are the sphincter-preserving anterior resection (ar) and the abdominoperineal resection (apr) - the latter results in a permanent colostomy. patients with generalised disease at diagnosis receive palliative treatment, which may include chemotherapy and radiotherapy as well as surgery. rectal cancer comes with a high risk of local recurrence, i.e. return of the tumour within the pelvis after a presumed curative resection. local recurrence is difficult to treat and often very painful and distressing for the patient. some local recurrences will be candidates for second line surgery, as is also true for some distant metastases. the aim of the qolirect study is to increase the knowledge about symptoms, functional impairments, quality of life (qol) and psychological and socioeconomic burden in an unselected population of rectal cancer patients. symptoms such as incontinence, pain, fatigue and impaired sexual function3 are common with this disease. bodily changes, caused by the treatment or the disease itself, may lead to functional impairments and psychological, social, emotional and economical restraints. conventional outcome measures such as morbidity and survival reveal little about these things.

Eligibility criteria:
inclusion criteria: * all patients presenting at the participating hospitals with newly diagnosed rectal cancer, regardless of stage at diagnosis and plans for treatment, will be eligible for inclusion. exclusion criteria: * age below 18 years at diagnosis. * no informed consent received or withdrawal of informed consent.

Keywords: rectal cancer quality of life abdominoperineal resection anterior resection palliative cancer treatment radio chemotherapy
collagenase in the treatment of dupuytrens disease

Conditions: Dupuytren's Disease

Summary: the purpose of the study is to determine if collagenase will reduce the degree of contracture in the primary joint in subjects with dupuytren's disease. this study was designed to be part of the larger clinical program, for adult patients with dupuytren's contracture with a palpable cord, where the data from 2 pivotal placebo-controlled studies (aux-cc-857 and aux-cc-859) and 7 non-pivotal studies were evaluated.

in a random, placebo controlled, double blind study, collagenase injection therapy will be investigated for it's ability to disrupt the dupuytren's cord. resultant cord disruption may obviate the need for patients to have surgery to correct the finger flexion contractures of dupuytren's disease.

Eligibility criteria:
inclusion criteria: * subjects were at least 18 years of age, of either sex or any race. * subjects had residual dupuytren's disease with a fixed-flexion deformity of the finger(s) of at least 20 degrees or greater, caused by a palpable cord. * subjects had a positive "table-top test" defined as the inability to simultaneously place their affected finger(s) and palm flat against a table top. * subjects must have been willing to participate in and complete the study, and comply with its procedures by signing an irb approved written consent form. * subjects must have been able to understand and adhere to the visit schedule. they must have been able to follow study procedures and instructions, and have agreed to report concomitant medications and adverse events accurately and consistently. * women of childbearing potential must have agreed to use an acceptable method of birth control or must have been surgically sterilized (hysterectomy or tubal ligation). women of childbearing age had a urine pregnancy test on day 0 (day of injection) prior to the injection. exclusion criteria * women who were nursing or who were pregnant (as evidenced by a positive urine pregnancy test at the time of enrollment). * subjects who had participated in an investigational drug trial within 30 days of enrollment in this study. * subjects who had received surgery for dupuytren's disease within 30 days of enrollment in this study. * subjects who had a known allergy to aa4500 or any of the inactive ingredients in the aa4500 injection. * subjects who had a known allergy to doxycycline. * subjects who had a medical condition that would have made them unsuitable for enrollment.

Keywords: dupuytren's contracture fixed flexion contracture
computer scan based analysing system on improving stroke management quality evaluation

Conditions: Acute Ischemic Stroke and Transient Ischemic Attacks

Summary: study is designed for two parts, a perspective, multi-center, historial control study and a randomized controlled study of acute ischemic stroke patients. for achieving the target of diagnosis and treatment kpi (key performance indicator) of ais patients and improving the defects of the traditional working mode, our center developed the medical records data acquisition and kpi statistics system based on computer scan. this method guarantees the authenticity of the data, it computes the kpi of the corresponding medical institutions in the corresponding period and gives feedback on a regular basis. based on the kpi feedback system, a multifaceted quality improvement intervention is conducted in the intervention group hospitals. this study aims to explore whether this new working mode can continuously improve the overall kpi in zhejiang province, and thus reflect the improvement of quality and standardization of medical service in ais patients.

study population:patients with acute ischemic stroke who were admitted to the hospital within 7 days after the initial symptom onset. program: there are multifaceted quality improvement interventions including: 1. implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols. 2. feedback system of performance measures. 3. expert online consultation. endpoints: primary outcome:increase of diagnosis and treatment key performance indicator for acute ischemic stroke patients; secondary outcome: the occurrence of ischemic stroke, total mortality, disability, and new clinical vascular events.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke or transient ischemic attacks patients exclusion criteria: * patients who losing his medical record of having the incomplete medical record
comparison of two positive expiratory pressure devices in stable copd patients

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: positive expiratory pressure (pep) therapy is a device aiding airway clearance and secretion mobilization, also prevent the small airway from collapsing. the purpose of this research is to compare two pep devices (pulmonica, rc-cornet) in stable copd patients. patients' compliance, satisfaction, 3 months and 6 months lung function test and life quality will be compared.

background : positive expiratory pressure (pep) therapy is a type of airway clearance therapy in which the patient exhales through a resistance, which helps to shift the pressure points that aid mobilization of sputum and prevent the lung from collapsing. pep therapy helps patients reduce the need for ventilatory support, improve hyperinflation and dyspnea. although pep devices are used, only a few studies have compared their beneficial effects and preference among copd patients. objective: the purpose of this research is to compare two pep devices (pulmonica, rc-cornet) in stable copd patients. . methods: a baseline assessment of the patient will be taken at the beginning, three months and the end of six months, including patients' ability to clear secretions via breathlessness, cough and sputum scale (bcss), patients' self-reported quality of life via st. george's respiratory questionnaire (sgrq) and copd assessment test (cat) scores, pt's satisfaction with each device, and cardio-pulmonary function via pulmonary function test and six minute walk test in three and six months. subsequently, patients will be randomly assigned a pep device (pulmonica, rc-cornet) and given instructions on how to properly use the device including frequency of pep therapy. each patient will receive a monthly follow-up call in order to determine adherence and satisfaction with pep therapy, also bcss, sgrq and cat scores.

Eligibility criteria:
inclusion criteria: * stable copd patients, younger than 80 years of age, older than 21 years and are willing to participate and give consent to participate exclusion criteria: * tracheotomy
urea cream treatment sorafenib-associated hsfr in hcc

Conditions: Hepatocellular Carcinoma

Summary: although sorafenib is effective and safe in patients with advanced hepatocellular carcinoma (hcc), it increases dermatologic toxicities, including hand-foot skin reaction (hfsr), which may have a negative impact on patient quality of life (qol). urea-based creams may have a prophylactic effect on sorafenib-induced hfsr in hcc patients.

mild hyperkeratosis is an early sign of hfsr and may sometimes be the only manifestation of sorafenib-associated hfsr. urea is useful for the treatment of hyperkeratotic conditions and has been recommended for the treatment of multitargeted kinase inhibitor-related hfsr . to our knowledge, no randomized, controlled trials to date have evaluated treatments to prevent/palliate sorafenib-associated hfsr. we therefore tested the prophylactic effects of a urea-based cream on the incidence of hfsr associated with sorafenib treatment of patients with advanced hcc.

Eligibility criteria:
inclusion criteria: * the patients with hepatocellular carcinoma will receive sorafenib per instructions of the package insert * the patients with hepatocellular carcinoma must be willing to participate in this study and provide the investigators with written consents; * the patients must be willing and able to complete the biweekly visits for the first 3 months; * the patients must be willing and able to fill in the patient's efficacy questionnaires. if the patients cannot use pens or pencils, the patient's acquaintances or the clinical staffs will complete these questionnaires based on the answers provided by the patients * the patients must discontinue all prior cancer treatment in at least 3 weeks before enrollment; * the patient's life expectancy is ≥3 months * the patients must provide written informed consents exclusion criteria: * the patients participated in other clinical trials * the patients received sorafenib therapy prior to enrollment * the patients combined other treatment or used other biological therapy, chemotherapy, experimental treatment or radiotherapy * the patient's sorafenib dosage exceeds 400mg, twice daily
cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

Conditions: Secondary Hyperparathyroidism

Summary: the 1st phase of the study will assess the acute biochemical response of pth, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. the 2nd phase of the study designed to evaluate the long term effects of cinacalcet on bmd (bone mineral density)and the levels of pth, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin d compounds.


Eligibility criteria:
inclusion criteria: * age older than 18 yrs * on hemodialysis for at least 3 months (thrice weekly) * ipth \>300pg/ml or histological evidence of secondary hyperparathyroidism * calcium \> 8.1 mg/dl exclusion criteria: * unstable clinical condition
fetal and neonatal thyroid in pregnancies with severe acute respiratory syndrome coronavirus 2 ( sars- cov2 ) covid-19

Conditions: Thyroid Dysfunction; Hypothyroidism; Hyperthyroidism

Summary: the thyroid gland has been shown to be a common target for covid 19 virus. babies born to mothers positive for covid 19 infections were noticed to have elevated thyroid stimulating hormone ( tsh ) levels on screening. thyroid function tests were monitored in these babies to determine presence of temporary or permanent thyroid disorders following covid 19 infections during pregnancy.

tsh estimation is carried out in all newborn babies in saudi arabia as a screening test for hypothyroidism. the first babies who were born to covid 19 positive mothers were noticed to have significantly abnormal high tsh values. all the data and studies on the effect of covid 19 on thyroid gland are from adult literature. hence with these results of tsh in the the newborns we designed this observational study to monitor the thyroid functions in infants of covid 19 positive mothers born in our hospital. the study confirmed presence of abnormal tsh and free thyroxine in these babies at birth and these babies were followed further after that for evidence of thyroid disorders.results of thyroid functions in the babies who born in the same period of the study to mothers without covid 19 infection were also recorded.

Eligibility criteria:
inclusion criteria: * all newborns exclusion criteria: * babies with congenital malformations

Keywords: tsh thyroid- stimulating hormone ft4 free thyroxine covid-19 corona virus disease pcr polymerase chain reaction sars cov2 severe acute respiratory syndrome miu milli-international unit
evaluating the role of immune responses in the emergence of protease inhibitor mutations

Conditions: Hepatitis C

Summary: the major goal of this project is to identify the role of the immune responses in the emergence of protease inhibitor mutants during therapy.

objective 1: evaluate the role of the immune responses in determining the emergence of hcv ns3 resistance mutation during protease inhibitor therapy hypothesis 1 (ht 1): low hla binding to peptides containing protease inhibitor resistance mutations is associated with the emergence of protease inhibitor mutants during therapy and failure of the treatment. hypothesis 2 (ht 2): a hole in t cell repertoire may allow emergence of protease inhibitor mutants during protease inhibitor therapy which leads to loss of the immune responses to these mutants and failure of treatment.

Eligibility criteria:
inclusion criteria: all chronically hcv-infected patients who fail peg-ifn and rbv therapy and are eligible for combined treatment with pi therapy will be enrolled. briefly, this includes: 1. male or female 2. age 18 to 65 3. chronic hcv infection evidenced by liver biopsy or persistent hcv viremia for \>6 months 4. treatment experienced and classified as non-responder or relapser to prior interferon-based therapy. exclusion criteria: 1. treatment naïve chronically hcv-infected patients. 2. patients with a history of inflammatory bowel diseases (ibd) or suspected ibd, autoimmune diseases, including rheumatoid arthritis, and any patients on systemic immunomodulators. 3. pregnancy 4. hiv

Keywords: hepatitis c hcv
identifying the neural basis of capability for suicide

Conditions: Major Depressive Disorder; Suicide; Suicidal Ideation; Psychiatric Illness

Summary: since capability for suicide involves overriding potential pain, and the opioid system plays a strong role in controlling pain perception, it follows that capability for suicide may be impacted by the opioid system. the goal of the proposed research is to identify the neural network underlying capability for suicide in order to determine if it can be a target for identifying high-risk individuals and for intervention.

little evidence exists distinguishing individuals with suicidal ideation (si) from those at risk for suicidal behaviour, illustrating the need for more comprehensive biomarkers for clinicians to guide their treatment approach and for new treatment avenues. current theories of suicide have suggested the importance of an individual's capability for suicide in predicting suicide attempt or death. building on this, yovell and colleagues (2016) provided important preliminary data that the opioid system affects suicide risk, but the neural mechanisms and their relationship to capability for suicide are unclear. the goal of the proposed research is to identify the neural network underlying capability for suicide using functional magnetic resonance imaging (fmri) in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Eligibility criteria:
inclusion criteria for patients: * age between 18-70 * capability of giving informed consent * not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels) exclusion criteria for patients: * lifetime history of any substance abuse, psychosis * current use of any opioid acting drugs * current use of any prescription pain medication * use of over the counter pain medications within 15 hours of brain scan * for daily users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 12 hours of brain scan * for as needed users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 2 weeks of brain scan. this is because non-daily use will have more unpredictable effects on brain imaging results than those who are using these medications on a regular basis. the 2 weeks will ensure the drug is not in the system. * medical condition requiring immediate investigation or treatment * participation in experimental treatment trials for the study duration. healthy control inclusion criteria: ages between 18 and 70 years, capable of giving informed consent, not pregnant or lactating, no lifetime history of axis i/ii disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.